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Hyperphosphorylated isoforms of the microtubule-as-
sociated protein tau are the major components of neu-
rofibrillary lesions in Alzheimer’s disease (AD). Protein
phosphatase (PP) 2A is a major phosphatase implicated
in tau dephosphorylation in vitro. Dephosphorylation of
tau can be blocked in vivo by okadaic acid, a potent
inhibitor of PP2A. Moreover, activity of PP2A is reduced
in AD brains. To elucidate the role of PP2A in tau phos-
phorylation and pathogenesis, we expressed a dominant
negative mutant form of the catalytic subunit C of
PP2A, L199P, in mice by using a neuron-specific pro-
moter. We obtained mice with high expression levels of
C L199P in cortical, hippocampal, and cerebellar neu-
rons. PP2A activity in brain homogenates of transgenic
mice was reduced to 66%. Endogenous tau protein was
hyperphosphorylated at distinct sites including the AT8
epitope Ser-202/Thr-205, a major AD-associated tau
phosphoepitope. AT8-positive tau aggregates accumu-
lated in the soma and dendrites of cortical pyramidal
cells and cerebellar Purkinje cells and co-localized with
ubiquitin. Our data establish that PP2A plays a crucial
role in tau phosphorylation. Our results also show that
reduced PP2A activity is associated with altered com-
partmentalization and ubiquitination of tau, resembling
a key pathological finding in AD.
Neurodegenerative diseases including Alzheimer’s disease
(AD)1 and frontotemporal dementia with parkinsonism linked
to chromosome 17 (FTDP-17) are characterized by neurofibril-
lary lesions that are composed of hyperphosphorylated iso-
forms of tau, a microtubule-associated protein (1, 2). Because
hyperphosphorylated tau binds poorly to microtubules and
thereby alters the stability of microtubules, tau hyperphospho-
rylation could affect other cytoskeletal constituents, intracellu-
lar transport, cellular geometry, and neuronal viability (3–6).
A fundamental question for understanding the mechanism of
neurofibrillary degeneration is why and how tau becomes ab-
normally hyperphosphorylated. To date, more than 20 phos-
phorylation sites have been identified in hyperphosphorylated
tau that are either serine or threonine residues. Several pro-
tein kinases have been implicated in the phosphorylation of tau
in AD (7–11), and there is accumulating evidence that reduced
activities of phosphatases are also involved (12, 13). The serine/
threonine-specific protein phosphatases PP2A, PP2B, and, to a
lesser extent, PP1 were shown to efficiently dephosphorylate
tau isolated from AD brain (14, 15). Pharmacological inhibition
in vivo further suggested that PP2A is involved in tau dephos-
phorylation (16–18). A role for PP2A in tau dephosphorylation
is also supported by the finding that PP2A is localized on
microtubules and that it binds directly to tau (19). FTDP-17-
associated mutations in tau induce a decrease in binding affin-
ity for PP2A, suggesting that altered interactions between
PP2A and tau may contribute to FTDP-17 pathogenesis (20).
The prolyl isomerase Pin1, which co-purifies with tau filament
preparations, catalyzes prolyl isomerization of specific Ser/Thr-
Pro motifs in tau and thereby restores the function of tau and
facilitates dephosphorylation by PP2A (21). Together, these
data demonstrate the importance of PP2A for tau function in
FTDP-17 and AD.
Attempts to investigate the role of PP2A in tau phosphoryl-
ation in vivo by a gene targeting approach in mice were com-
plicated by the fact that the selective knockout of the PP2A
catalytic subunit C was embryonically lethal (22, 23).
Therefore, we expressed a dominant negative mutant form of
the catalytic subunit C of PP2A, L199P (24, 25), under the
control of a neuron-specific promoter in transgenic mice. In
brain homogenates of transgenic mice, PP2A activity was
chronically reduced to 66% of the activities in wild-type mice.
Endogenous tau was distinctly phosphorylated at the AT8
epitope Ser-202/Thr-205 and at the phosphorylated serine 422
(pS422) epitope Ser-422. It accumulated in aggregates in the
somatodendritic compartment and was co-localized with ubiq-
uitin, reflecting an early step in neurofibrillary lesion forma-
tion in AD.
EXPERIMENTAL PROCEDURES
Constructs and Transgenic Mice—The cDNA of the human PP2A C
mutant L199P was isolated from yeast plasmid YEpDE2.5.12 that
carries a 978-base pair HindIII/BamHI fragment encoding the HA-
PP2AC-2512 mutant allele. The single hemagglutinin epitope present
in this allele is located immediately downstream of the start codon. The
HA-PP2AC-2512 allele contains the T196C transition mutation encod-
ing a L199P amino acid substitution (numbering is for the untagged
PP2AC). It also encodes a C215T base change, which is a silent
mutation (24). The 978-base pair fragment was subcloned into the
neuron-specific murine Thy1.2 expression vector (26, 27). Vector se-
quences were removed, and DNA was purified by ultracentrifugation
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for 30 min at 40,000 rpm (TLA45 rotor) to remove residual agarose
before microinjection. Transgenic mice were produced by pronuclear
microinjection of B6D2F1  B6D2F1 embryos, as described previously
(28). Founders were identified by polymerase chain reaction analysis of
lysates from tail biopsies using oligonculeotides O-144 (5-GTTCACC-
AAGGAGCTGGACCAG-3) and O-145 (5-ACAGGAAGTAGTCTGGG-
GTACG-3), and an amplification product of the 915-base pair fragment
was obtained. Founder animals were intercrossed with C57BL/6 mice to
establish lines.
Antibodies—The following tau antibodies directed against different
phosphoepitopes (Table I) of tau were used: (a) AT8 (Innogenetics Inc.,
Temse, Belgium; 1:20 dilution) (29), (b) AT100 (Innogenetics Inc.; 1:100
dilution) (30), (c) AT180 (Innogenetics Inc.; 1:50 dilution) (30), (d) 12E8
(Dr. Peter Seubert, Elan Pharmaceuticals, South San Francisco, CA;
1:100 dilution) (31), (e) TG3 (Dr. Peter Davies, Bronx, NY; 1:20 dilution)
(32), (f) PHF1 (Dr. Peter Davies; 1:50 dilution) (33), (g) AD2 (Dr.
Chantal Mourton-Gilles, Lille, France; 1:500 dilution) (34), (h) MC1 (Dr.
Peter Davies; 1:10 dilution) (35), (i) R145d (Dr. Khalid Iqbal, Staten
Island, NY; 1:3000 dilution) (36), and (j) S199P (Dr. Andre´ Delacourte,
Lille, France; 1:100 dilution) (37, 38). For immunohistochemistry, we
used conditions that have been previously optimized in tau transgenic
mouse models (39). To detect ubiquitin, a commercially available poly-
clonal anti-ubiquitin antibody (Calbiochem) was used at a dilution of
1:100. For immunoblotting, the following anti-tau antibodies were used:
phosphorylation-independent monoclonal antibody TAU-5 (Neo Mark-
ers Inc., Fremont, CA; 1 g/ml) and phosphorylation-dependent anti-
bodies/antisera AT8 (1:150 dilution), AT100 (1:1000 dilution), AT180
(1:150 dilution), AD2 (1:10,000 dilution), pS422 (BIOSOURCE; 1:500
dilution) (40), and S199P (1:5000 dilution). For detection of the HA
epitope by immunohistochemistry and immunoblotting, two monoclonal
anti-HA antibodies (Roche Molecular Biochemicals (immunohistochem-
istry, 1:200 dilution; immunoblotting, 1:500 dilution) and Santa Cruz
Biotechnology, Santa Cruz, CA (immunohistochemistry, 1:100 dilution;
immunoblotting, 1:500 dilution)) and a polyclonal anti-HA antibody
(Santa Cruz Biotechnology; immunohistochemistry, 1:500 dilution; im-
munoblotting, 1:1000 dilution) were used. The rabbit anti-PP2AC an-
tiserum V598A (Promega, Madison, WI) directed against a carboxyl-
terminal sequence shared between human and mouse PP2AC and
PP2AC was used at a 1:100 dilution for immunoblot analysis. For
immunofluorescence, secondary antibodies were obtained from Molec-
ular Probes (ALEXA-FLUORTM series; Eugene, OR), and for immuno-
blotting, horseradish peroxidase-conjugated secondary antibodies (Vec-
tor Laboratories, Burlingame, CA) were used.
Immunohistochemistry—Brains from 12-month-old transgenic mice
and an equal number of age-matched control mice (C57BL/6 mice) were
used for immunohistochemical analysis. Animals were perfused tran-
scardially with 4% paraformaldehyde in saline/sodium phosphate
buffer, pH 7.4. Immunohistological stainings were performed on 4-m
methanol-permeabilized, paraffin-embedded parasaggital sections from
brain by using standard published procedures (22). In addition, 40-m
vibratome sections were permeabilized with 0.1% Nonidet P-40 (Cal-
biochem). Some of the sections were pretreated with either 5 g/ml
proteinase K or 0.1% Triton X-100 in Tris-buffered saline or phosphate-
buffered saline at 37 °C for 2.5 min for signal enhancement. Sections
were dehydrated in an ascending series of ethanol and flat embedded
between glass slides and coverslips in Mowiol 4-88 (Roche Molecular
Biochemicals) containing 2.5% (w/v) diazabicyclo[2.2.2]octane (Sigma).
Northern Blot and Immunoblots—RNA was prepared according to
the manufacturer’s recommendations (RNeasy; Qiagen). 20 g of total
RNA were separated by formaldehyde gel electrophoresis and trans-
ferred to a nylon membrane (Hybond N; Amersham Pharmacia Bio-
tech). Prehybridization was done for 30 min in 1% (w/v) bovine serum
albumin, 0.2 M sodium phosphate buffer, pH 7.2, 35% (v/v) deionized
formamide, 1 mM EDTA, and 7% (w/v) SDS. For hybridization, a -32P-
labeled oligonucleotide hybridizing to exon 7 of the human PP2A C
gene (5-GACATGTGGCTCGCCTCTAC-3) was used (22). For normal-
ization, a random-labeled probe derived from a 2-kilobase human -ac-
tin cDNA fragment was used. After hybridization, membranes were
washed several times under stringent conditions at 65 °C. Membranes
were exposed to a Kodak x-ray film at 80 °C using an intensifying
screen.
To analyze tau expression and phosphorylation, brains from trans-
genic and control mice were weighed and Dounce homogenized in 2.5%
(v/v) perchloric acid in phosphate-buffered saline, allowed to stand on
ice for 30 min, and centrifuged for 10 min at 10,000  g. The superna-
tants were dialyzed against 50 mM Tris-HCl, pH 7.4, 1 mM dithiothre-
itol, and 0.1 mM phenylmethylsulfonyl fluoride and used for immuno-
blot analysis as described previously, using equal amounts of protein
extracts (41). Staining of the membranes with Ponceau S was included
to confirm loading of comparable amounts of protein. To analyze levels
of PP2A expression, protein extracts were prepared according to stand-
ard procedures (42) and normalized for protein contents using the DC
Protein Assay from Bio-Rad (Hercules, CA). Extracts were separated by
10% SDS-polyacrylamide gel electrophoresis, followed by electro-
phoretic transfer onto a nitrocellulose membrane (Hybond-ECL; Amer-
sham Pharmacia Biotech). The membrane was blocked and reacted
with primary and horseradish peroxidase-conjugated secondary anti-
bodies as described previously (42).
Protein Phosphatase Activity Measurements—Total brain extracts
from 5- and 12-month-old mice were prepared with a Teflon homoge-
nizer (15 strokes at 100 rpm) in 1 Tris-buffered saline and 1% (v/v)
Triton X-100 in the presence of protease inhibitors (CompleteTM with
EDTA; Roche Molecular Biochemicals). Phosphatase assays were per-
formed with these extracts using the phosphatase kit V2460 from
Promega. First, endogenous free phosphate was removed from the
homogenates, and then the homogenates were normalized for protein
content. Release of phosphate from a chemically synthesized phos-
phopeptide (RRA(pT)VA; pT  phosphothreonine) (43) was measured
over a period of 45 min. Homogenates were prepared in duplicate from
six transgenic and control brains, and two assays were performed with
each homogenate. Mean values and standard deviations were calcu-
lated. The amount of released phosphate was determined by measuring
the absorbance of a molybdate-malachite green-phosphate complex at
595 nm. The interassay variance was 1%. Brain homogenates were
also incubated with okadaic acid (okadaic acid, sodium salt; Calbio-
chem), a potent inhibitor of PP2A, at concentrations of 1 and 10 nM,
respectively.
RESULTS
Neuronal Expression of the Dominant Negative Mutant Form
of PP2A C, L199P—The neuron-specific elements of the
mouse Thy1.2 promoter were used to express the cDNA of
human PP2A C mutant L199P (Fig. 1A). This expression
vector mediates a postnatal neuronal expression of the inserted
cDNA (44). The L199P mutant has previously been shown to
act as a dominant negative mutant of PP2A in Saccharomyces
cerevisiae (24). A HA epitope was fused amino-terminally (24)
to facilitate later detection of the mutant protein. The construct
was microinjected into oocytes as described previously (28), and
six founders were obtained, four of which transmitted the
transgene in a Mendelian fashion. These lines expressed PP2A
C L199P mRNA in brain, as determined with a human PP2A
C exon 7-specific oligonucleotide as probe (Fig. 1B, top panel)
(22). To control for equal loading, a human -actin probe was
used (Fig. 1B, bottom panel). An antibody directed against the
HA epitope of the transgene detected on immunoblots a protein
with the expected molecular mass in three transgenic lines.
This protein was absent from the wild-type litter mate control
(Fig. 1C, top panel). Immunoblotting of the same protein ex-
tracts with an antibody directed against a conserved epitope
between human and murine PP2A C revealed that the total
amount of PP2A C was not significantly changed upon expres-
sion of the mutant PP2A C L199P protein (Fig. 1C, bottom
panel). For comparison, in heterozygous PP2A C knockout
mice, PP2A C protein levels were identical to wild-type levels
(22), suggesting that protein levels of PP2A C are tightly con-
trolled (45, 46). PP2A C L199P mice were overtly normal. Size
and fertility were not reduced compared with nontransgenic
litter mates.
The expression pattern of PP2A C L199P was determined
by immunohistochemistry with an antibody directed against
the HA epitope (Fig. 2). This staining revealed a neuronal,
cytoplasmic expression in most brain areas including the Pur-
kinje cells of the cerebellum (Fig. 2A), layers I-V of the cortex
(Fig. 2B), and the hippocampal formation (Fig. 2C), whereas no
staining was detected in the same brain areas of wild-type mice
(Fig. 2, D–F). Together, these data show that the PP2A C
mutant L199P is also expressed in such brain regions as the
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hippocampus and the cortex, which are affected by tau pathol-
ogy and neurodegeneration in AD.
Reduction of PP2A Activity in Transgenic Mice—To deter-
mine whether expression of the mutant PP2A C L199P in
brain caused a long-term, chronic inhibition of PP2A activity,
brain homogenates from 5- and 12-month-old transgenic and
age-matched wild-type mice were analyzed for phosphatase
activity by a colorimetric assay. Homogenates were obtained
from six brains each, and activities were determined in dupli-
cate samples by using as substrate a phosphopeptide that can
be dephosphorylated by PP2A, PP2C, and, with substantially
lower efficiencies, PP2B (47). PP1, in contrast, does not dephos-
phorylate peptide substrates at all (47). Assays were done with
total extracts in a buffer optimized for PP2A to inhibit cation-
dependent PP2B and PP2C activities. After 10 min of incuba-
tion, the assay revealed a reduction in activity of 34  9% (n 
6; S.E. 3%) in PP2A C L199P as compared with control
homogenates (Fig. 1D). A similar decrease of PP2A activity was
found in 5- and 12-month-old mice (data not shown). To further
confirm that the measured decrease in phosphatase activity
was due to a reduced activity of PP2A, brain homogenates were
incubated with okadaic acid, a potent inhibitor of PP2A. Con-
centrations of 10 nM okadaic acid induced a half-maximal re-
duction of phosphatase activity in both wild-type and trans-
genic brain homogenates, normalized for the respective
activities in wild-type and transgenic brain homogenates in the
absence of okadaic acid. Because the ratios remained the same,
our data indicate that PP2A and not another serine/threonine-
directed phosphatase is inhibited in brains of PP2A C L199P
transgenic mice (data not shown). Additionally, assays were
performed in the presence of 100 mM EGTA, which, as com-
pared with standard assay conditions, had no influence on the
ratio of inhibition, suggesting that PP2B is not a significant
contaminant. Together, these data demonstrate that a neuro-
nal, postmitotic expression of PP2A C L199P was sufficient to
induce a chronic, 34% reduction of PP2A activity in brains of
transgenic mice.
Distinct Phosphorylation, Aggregation, and Ubiquitination
of Endogenous Tau Protein—To determine the functional
consequences of reduced PP2A activity in mouse brains, we
analyzed the phosphorylation and localization of the micro-
tubule-associated protein tau by immunoblotting and
immuno histochemistry.
Immunoblot analysis of tau protein in brain from transgenic
mice as compared with controls revealed neither changes in tau
expression levels nor changes in the relative distribution of the
three murine tau isoforms (Fig. 3). To determine whether tau
phosphorylation was altered in transgenic brain, we used a
panel of different phosphorylation-dependent antibodies (Table
I; Fig. 3). Tau phosphorylation was not detectable at the S199P
and AT180 epitopes, and the AT100 and AD2 epitopes were not
phosphorylated differently in brains from transgenic mice as
compared with control brains. Phosphorylation of the AT8
epitope was only barely detectable, if detectable at all. In con-
trast, this epitope was readily detectable in brain extracts
obtained from both human wild-type and FTDP-17 mutant tau
transgenic mice (Fig. 3) (27, 28, 39). The pS422 epitope was
phosphorylated in PP2A L199P transgenic brains, but not in
controls (Fig. 3).
To map the regional phosphorylation of tau in brain,
parasaggital sections from transgenic mice expressing PP2A
C L199P and age-matched controls were stained with a panel
of phosphorylation- and conformation-dependent anti-tau an-
tibodies (Table I), using conditions previously optimized in tau
transgenic mouse models (27, 39). Stainings with antibody AT8
revealed that tau was phosphorylated at the epitope Ser-202/
Thr-205 in several brain areas of L199P transgenic mice. AT8-
immunoreactive tau was present in axonal (Fig. 4A) and soma-
todendritic compartments of cerebellar Purkinje cells (Fig. 4,
C–F). In cortical neurons, expression levels were highest in
layer IV (Fig. 5, A and C–G). No AT8 immunoreactivity was
detected in age-matched nontransgenic controls (Figs. 4B and
5B) These data show that inhibition of PP2A by expression of a
mutant form of PP2A C caused hyperphosphorylation of the
tau epitope Ser-202/Thr-205 and aggregation of tau in the
somatodendritic compartment.
Because additional phosphoepitopes of tau have been shown
to be dephosphorylated by PP2A in vitro (15, 36, 48–52), we
included the phosphorylation-dependent anti-tau antibodies
AT100, AT180, 12E8, PHF1, AD2, R145d, S199P, and TG3 in
our analysis (Table I). Immunohistochemical analysis revealed
no significant differences between transgenic and control
brains for any of these epitopes. Even antiserum R145d that
was reactive in immunoblots did not reveal phosphorylation of
epitope Ser-422 by immunohistochemistry. This suggests that
this epitope, in contrast to the AT8 epitope, is phosphorylated
in many neurons of our L199P mice at only very low levels.
Strong staining of hyperphosphorylated tau by this antiserum
was detected in brain sections from pharmacologically treated
P301L mutant tau transgenic mice under identical experimen-
FIG. 1. Transgenic mice expressing a dominant negative mu-
tant form of PP2A C, L199P. A, the neuron-specific elements of the
mouse Thy1.2 promoter were used to express the cDNA of human PP2A
C mutant L199P in transgenic mice. To discriminate transgenic mu-
tant from endogenous wild-type PP2A C, a HA epitope was fused to
the amino terminus of PP2A C L199P. B, Northern blot analyses
revealed expression of PP2A C L199P mRNA in every second trans-
genic line. C, whereas mRNA levels were different for lines 19 and 21,
protein levels appeared to be similar as determined by Western blot
analysis using an antibody directed against the HA epitope (C, top
panel). Total PP2A C levels were not significantly different in trans-
genic brain homogenates as compared with wild-type brain homoge-
nates, as determined with antiserum V598A (C, bottom panel). D,
reduced protein phosphatase activities in brain extracts of PP2A C
L199P transgenic mice. Brain homogenates were obtained from trans-
genic (tg) and wild-type (wt) mice, and phosphatase activities were
measured in the presence of 2 mM EDTA (n  6). Phosphatase activity
was reduced to 66  9% (n  6) in brain extracts of transgenic mice
compared with wild-type mice. Significant differences (), as compared
with wild-type mice, are at the p  0.01 level (U test).
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tal conditions,2 which excludes the possibility that antiserum
R145d was not reactive under the conditions employed. Soma-
todendritic localization of tau was not accompanied or preceded
byanalteredconformationoftauasdeterminedbyconformation-
dependent anti-tau antibodies TG3 and MC1 (Table I).
Interestingly, AT8 immunoreactivity in the cell bodies al-
ways appeared granular, which could be due to aggregation of
abnormally localized and phosphorylated tau. Because aggre-
gated tau is highly ubiquitinated in AD brains, we analyzed
transgenic and control brains by confocal microscopy for AT8
and ubiquitin staining (Fig. 6). We found that AT8 and ubiq-
uitin co-localized in the majority of AT8-positive tau aggregates
(Fig. 6C). However, some of the tau aggregates were ubiquitin-
negative, and this did not correlate with the size of the AT8-
positive granular material or the number of AT8-postive
aggregates/cell.
DISCUSSION
Our data show that expression of a dominant negative mu-
tant form of the catalytic subunit C of PP2A in transgenic
mice, in up to 1-year-old mice, was sufficient to permanently
reduce PP2A activity by 34% as compared with wild-type con-
trols. The reduced activity was associated with a distinct neu-
ronal hyperphosphorylation of the microtubule-associated pro-
tein tau at the AT8 epitope Ser-202/Thr-205 and at the pS422
epitope Ser-422 and the accumulation of hyperphosphorylated
tau in both the axonal and somatodendritic compartments.
Furthermore, AT8-positive tau aggregates were partly co-local-
ized with ubiquitin, suggesting that tau was targeted for
degradation.
Impaired PP2A Function in Mice Expressing Mutant
L199P—Deregulation of phosphorylation-dephosphorylation
mechanisms has been postulated in AD (2, 41, 53–57). PP2A,
PP2B and, to a lesser extent, PP1 were found to be involved in
the dephosphorylation of tau in normal brain (18, 58, 59). In
our studies, we showed that expression of the human PP2A C
mutant L199P in brains of transgenic mice reduced PP2A
activity by 34% by using as substrate a short phosphopeptide
that is preferentially dephosphorylated by PP2A (47).
Mutant L199P was initially isolated in a mutagenesis study
aimed at predicting the role of specific PP2A C residues in
yeast (24). These studies showed that L199P bound the endog-
enous yeast PR65/A structural subunit, suggesting that, al-
though catalytically impaired, it folded sufficiently to bind
PP2A-interacting proteins, thereby contributing to its interfer-
ing effect on PP2A C function. Because the core dimer com-
posed of the catalytic C and the structural PR65/A subunit
serves as an essential scaffold for the recruitment of B-type
regulatory subunits (60–64), PP2AC mutant L199P may ef-
fectively titrate other subunits, interfering with targeting
and/or substrate specificity of the wild-type enzyme (24, 25).
2 Gotz, J., Chen, F., van Dorpe, J., and Nitsch, R. M. (2001) Science,
293, 1491–1495.
FIG. 2. Neuronal expression of mu-
tant PP2A C L199P protein in trans-
genic mice. Parasaggital vibratome sec-
tions of transgenic mice (A–C) and age-
matched wild-type controls (D and E)
were stained with an antibody directed
against the HA tag fused to the C L199P
protein. Immunoreactivity of mutant
PP2A C L199P was detected throughout
the brain of transgenic mice. Cerebellar
Purkinje cells (A), cortical pyramidal neu-
rons (B), and pyramidal neurons of the
CA1 region of the hippocampus (C) re-
vealed a cytoplasmic and partly granular
perinuclear staining. This staining was
absent in the corresponding brain regions
of wild-type mice (D–F). Scale bar,
100 m.
FIG. 3. Immunoblot analysis of tau protein in brain from trans-
genic mice. Tau protein extracted from the brains of transgenic and
control mice was treated with alkaline phosphatase and analyzed by
immunoblotting using phosphorylation-independent anti-tau antibody
Tau-5 (lanes 1 and 2). No differences in isoform composition were
revealed. Tau proteins from a human wild-type tau transgenic brain
(27) before and after alkaline phosphatase treatment (lanes 3 and 4)
were analyzed with phosphorylation-dependent anti-tau antibody AT8.
The molecular mass  103 is shown to the left. Tau proteins from the
brain of transgenic (lanes 5, 7, 9, 11, 13, and 15) and control (lanes 6, 8,
10, 12, 14, and 16) mice were analyzed by immunoblotting using the
phosphorylation-dependent anti-tau antibodies AT8, AT100, AT180,
AD2, pS422, and S199P.
TABLE I
Specificity of anti-tau antibodies employed in this study
Several phosphorylation- and conformation-dependent antibodies
were used in this study. The respective phosphoepitopes are listed.
Antibody Phosphorylationsitea Specificity
b Reference
no.
S199P Ser-199 P 37 and 38
AT8 Ser-202/Thr-205 P 29
AT100 Thr-212/Ser-214 P 30
AT180 Thr-231/Ser-235 P 30
12E8 Ser-262/Ser-356 P 31
PHF1 Ser-396/Ser-404 P 33
AD2 Ser-396/Ser-404 P 34
R145d Ser-422 P 36
pS422 Ser-422 P 40
TG3 Thr-231/Ser-235 P, C 32
MC1 C 35
a Numbered according to the largest isoform of human brain tau.
b P, phosphorylation-dependent epitope; C, conformation-dependent
epitope.
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Because expression of the human PP2A C mutant interfered
with murine PP2A function in our transgenic mice, it is likely
that the mechanism of PP2A inhibition is identical to that in
yeast. This suggests a functional conservation between murine,
human, and yeast PP2A that reflects conservation at the se-
quence level (65).
In a related study, a mutant form of the structural subunit A
of PP2A with impaired binding of regulatory B subunits was
expressed under control of the -actin promoter in transgenic
mice. This expression caused a 30% decrease in the activity of
the holoenzyme in heart homogenates (66, 67). In our L199P
mutant mice, a reduction of PP2A activity similar to that found
in the PP2A subunit A mutant mice was seen. Despite differ-
ences in the construct design and expression pattern, the mech-
anisms responsible for the reduction in PP2A activity are likely
similar. They involve a titration of either the A or the C subunit
and thereby prevent the formation of active holoenzyme com-
plexes. This approach suggests the expression of mutant forms
of PP2A under the control of additional promoters to assess the
role of PP2A during development and in terminally differenti-
ated tissues.
Distinct Phosphorylation and Aggregation of Tau—Phospho-
rylation in general and that of tau in particular are determined
by the relative activities of kinases and phosphatases. PP2A
can exert its effects on substrates either directly or indirectly
via dephosphorylation of substrate-specific kinases (13, 46).
FIG. 4. Tau phosphorylation in the cerebellum of PP2A C L199P mutant mice. Parasaggital sections of paraffin-embedded brains from
transgenic mice expressing PP2A C L199P (A, C, E, and F) and age-matched wild-type mice (B and D) were stained with anti-tau antibody AT8
(red; B and C). AT8 immunoreactivity was detected in axons (A) and cell bodies of cerebellar Purkinje cells (C), demonstrating phosphorylation of
tau at epitope Ser-202/Thr-205. No AT8 immunoreactivity was found in age-matched wild-type controls (B and D). In PP2A C L199P mutant mice,
AT8-positive tau accumulated in cell bodies of Purkinje cells and formed small aggregates. A single Purkinje cell is shown (E and F, differential
interference contrast image). Scale bar: 100 m (A and B), 20 m (C and D), and 5 m (E and F).
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Here, we show that reduction of PP2A activity in transgenic
mice was sufficient to induce a distinct hyperphosphorylation
of the AT8 epitope Ser-202/Thr-205 of tau (Table I). This find-
ing is consistent with several studies that suggested a role of
PP2A in dephosphorylating this epitope (15, 51, 55, 68, 69).
Short treatments with the PP2A inhibitor okadaic acid on rat
brain slices increased both tau levels and the phosphorylation
of the Tau-1 epitope (Ser-199/Ser-202) (18), which overlaps, in
parts, with the AT8 epitope (Ser-202/Thr-205) of tau. In our
mice, reduction of PP2A activity induced the AT8 epitope, but
not epitope S199P, suggesting that Ser-202 is a substrate of
PP2A. Obviously, other phosphatases fail to take over the func-
tion of PP2A in dephosphorylating the AT8 epitope, whereas
they may compensate for the reduced PP2A activity and thus
FIG. 5. Tau phosphorylation in the cortex of PP2A C L199P mutant mice. Parasaggital sections of paraffin-embedded brains from
transgenic mice expressing PP2A C L199P (A and C (at higher magnification)) and age-matched wild-type mice (B) stained with anti-tau antibody
AT8. In PP2A C L199P mutant mice, as for Purkinje cells, AT8-positive tau accumulated in the cell bodies of cortical neurons and formed small
aggregates (two representative neurons: E and D, differential interference contrast image; and G and F, DIC image). Scale bar: 100 m (A and B),
30 m (C), and 5 m (E–G).
FIG. 6. Aggregated tau co-localizes with ubiquitin. Parasaggital sections of transgenic mice were stained with the AT8 antibody (A, shown
in red) and an anti-ubiquitin antibody (B, shown in green) and analyzed by confocal microscopy. Serial sections of confocal images were recorded
sequentially. In the Purkinje cells of the cerebellum, hyperphosphorylated tau accumulated in large, perinuclear aggregates that were co-stained
with ubiquitin (C, shown in yellow). Not all AT8-positive aggregates are also ubiquitin-positive (A, shown in red). m, molecular layer; g, granular
layer; scale bar, 20 m.
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dephosphorylate tau at the S199 epitope. Strong reactivity of
the AT8 epitope by immunoblotting was not observed because
few cells in the brain significantly phosphorylated this epitope.
These findings are consistent with those obtained in transgenic
mice that express human tau under the control of the human
Thy1 promoter. In these mice, the AT8 epitope also was phos-
phorylated in few neurons and therefore failed to reveal phos-
phorylation by immunoblotting (28).
Treatment of brain slices with okadaic acid induced addi-
tional phosphoepitopes of tau including 12E8 and R145d. By
immunoblotting, we found that epitope Ser-422, a substrate of
antisera R145d and pS422, was phosphorylated in transgenic
brain homogenates. There are two possible reasons for the
failure to detect hyperphosphorylation of this epitope by im-
munohistochemistry: (a) either low levels of tau may be phos-
phorylated at epitope Ser-422 in many neurons in transgenic
mice, or (b) the antiserum may not be suitable for immunohis-
tochemistry. The latter is unlikely because both antisera detect
tau hyperphosphorylated at Ser-422 in pharmacologically
treated P301L mutant tau transgenic mice.2 Remarkably,
transgenic mice expressing human wild-type tau under the
control of the murine Thy1.2 promoter also reveal weak phos-
phorylation of the Ser-422 epitope by immunoblotting but fail
to do so by immunohistochemistry (27). In vitro studies sug-
gested that in addition to AT8 and R145d/pS422, tau phospho-
epitopes AD2, 12E8, PHF1, and AT180 (15, 36, 48–52) are also
dephosphorylated by PP2A. However, the 34% reduction of
PP2A activity in our transgenic mice was not associated with
changes in the phosphorylation- and/or conformation-depend-
ent tau epitopes PHF1 and AD2, 12E8, AT100, AT180, S199P,
MC1, and TG3 (Table I). The phosphorylation-dependent
epitopes are conserved between mice and men, whereas murine
tau may not adopt a conformation that is recognized by the
conformation-dependent antibodies MC1 and TG3.
Previous studies showed that in brain homogenates of AD
patients compared with those of control subjects, tau phospha-
tase activity was decreased by 30% (12), and PP2A mRNA
expression was quantitatively decreased in AD (70). Because
the reduction of PP2A activity in PP2A C L199P transgenic
mice resembled that in AD brain (12), and because the AT8
epitope is an early epitope in AD pathogenesis (71), our data
support a critical role of PP2A in the early stages of AD.
Interestingly, in our mice, AT8 staining was most pro-
nounced in the cerebellum and cortex, whereas staining was
weaker in the hippocampus. This correlates with the expres-
sion level of the mutant L199P, which was much lower in the
hippocampus as compared with cerebellum and cortex. Differ-
ences in AT8 staining may also be due to differences in the
activities of kinases and phosphatases in different brain areas.
This view is supported by the finding that in brains of trans-
genic mice lacking the catalytic subunit A of PP2B, hyper-
phosphorylation of tau was restricted to the axonal mossy fiber
projection of the hippocampus (72).
In AD, the axonal protein tau is hyperphosphorylated and
accumulates in the somatodendritic compartment, where it
eventually aggregates, forming filaments. With maturation,
this tau becomes ubiquitinated (73–75). In our mice, some of
these steps were recapitulated. A fraction of AT8-positive tau
was present not only in axonal but also in somatodendritic
compartments, where it accumulated as perinuclear aggre-
gates that partly co-localized with ubiquitin, suggesting that
tau is targeted for degradation. Interestingly, after deafferen-
tation of the hippocampus, similar AT8-positive granules form
that resemble those present in argyrophilic grain disease, an-
other AD-related tauopathy (76, 77).
Taken together, our results support the hypothesis that
PP2A is involved in the phosphorylation of tau in vivo. Our
PP2A C L199P mice are characterized by a chronic reduction
of PP2A activity in brain that is sufficient to induce both
hyperphosphorylation and somatodendritic accumulation of
tau. This suggests that a defect in PP2A activity contributes to
the pathogenesis in AD (5, 19, 78). Mating of PP2A dominant
negative mutant mice with AD transgenic models, including
tau filament-forming mice (39, 79), will allow the role of PP2A
in AD to be further addressed.
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